(Alliance News) - GSK PLC on Tuesday said the US Food & Drug Administration accepted its supplemental biologics licence application for endometrial cancer treatment dostarlimab, or Jemperli, after it was granted priority review in September. Read More
(Alliance News) - Unilever PLC has appointed executive search firm Spencer Stuart to find a replacement for Chair Nils Andersen, Bloomberg reported on Monday, citing "people familiar with the situation". Read More
(Alliance News) - hVIVO's involvement in the approval of pharmaceutical giant Pfizer's new vaccine Abrysvo should support interest in its services, according to Liberum. Read More
Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Chief Executive Officer Neil Clark steps down immediately "to pursue new challenges". Clark will "support [Destiny] for a limited period to ensure an orderly handover." Non-Executive Director Debra Barker will serve as interim CEO until Destiny appoints a permanent replacement. Barker has held "key roles" at Novartis AG and Polyphor AG, now named Spexis AG. She also has previously worked at Roche Holding AG, Polyneuron Pharmaceuticals AG and GSK PLC. Read More
(Alliance News) - Stocks in London ended the week broadly higher on Friday, with strong performances from blue-chips Beazley and GSK helping to offset weak economic growth data for the UK economy. Read More
(Alliance News) - Stock prices in London were mixed at midday on Friday as investors digested a weak GDP reading for the UK, a day after the Bank of England took the country's interest rates up to a 15-year-high. Read More
(Alliance News) - GSK PLC on Friday reported positive preliminary results from a phase 3 trial regarding its 5-in-1 meningococcal ABCWY vaccine candidate. Read More
(Alliance News) - GSK PLC on Friday welcomed a legal ruling in Canada that threw out a proposed class action made on behalf of users of a heartburn drug. Read More
(Alliance News) - Stocks in London were called to open higher on Friday, after data showed the UK economy expanded 0.1% over the first three months of the year. Read More
(Alliance News) - GSK PLC's respiratory syncytial virus vaccine Arexvy has "best-in-class potential" following its approval by the US Food & Drug Administration on Wednesday last week, according to analysts at Berenberg. Read More
(Alliance News) - Stocks in London were called to open lower on Thursday, amid a busy day for company earnings and an interest rate decision by the EU's central bank in the afternoon. Read More
GSK PLC - Brentford, London-based pharmaceutical firm - Announces the US Food & Drug Administration approves Arexvy, the world's first respiratory syncytial virus vaccine for older adults. States approval enables adults aged 60 years and older to be protected from RSV disease for the first time. Explains the approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy in older adults, including those with underlying medical conditions, and in those with severe RSV disease. Plans US launch before the 2023/24 RSV season. Read More
(Alliance News) - Stocks in London were higher at the close on Wednesday as investor waited with bated breath for the US Federal Reserve's next interest rate decision. Read More
(Alliance News) - GSK PLC on Thursday said its respiratory syncytial virus vaccine candidate has gained positive opinion from the European Medicines Agency body. Read More
Schroders PLC - London-based investment manager - Hires Richard Oldfield to succeed Richard Keers as chief financial officer and an executive director. Oldfield currently is vice chair & global markets leader at accountants PricewaterhouseCoopers. Oldfield will join Schroders on October 2, and Keers will depart on December 31 after 10 years with the company. At Schroders, Oldfield will be responsible for "firm-wide operations" and for "financial management, risk management, technology, capital and treasury". Read More
(Alliance News) - European equities closed lower on Wednesday, with lingering banking sector worries hurting sentiment, while tech stocks outperformed wider markets in New York after well-received earnings overnight. Read More
(Alliance News) - Derren Nathan, head of equity research at Hargreaves Lansdown, said that GSK PLC got off to a "healthy start" to 2023, despite the pharmaceutical firm reporting a slip in first quarter sales. Read More
(Alliance News) - Brentford, London-based GSK PLC on Wednesday reported a slip in quarterly sales, but confirmed its 2023 guidance. Read More
(Alliance News) - Stocks in London were set to open lower on Wednesday as worries about the US banking sector returned. Read More